Seeking Alpha
 

Celgene Corporation (CELG)

- NASDAQ
Show Summaries  |  Hide Summaries
  • Jul. 2, 2013, 9:55 AM
    Celgene (CELG) has paid $15M for the right to first negotiation for the Neo-Kidney Augment product of closely held Tengion. The product is in Phase I trials and is designed to restore renal function in patients with chronic kidney disease. Celgene has also obtained an exclusive option to acquire assets such as Tengion's technology for growing esophageal implants, and it has received stock warrants. Celgene invested $5M in Tengion in October 2012. (PR)
    | Comment!
  • Jul. 1, 2013, 8:16 AM
    Onyx (ONXX) shares rocket 51% to $130.98 after the company says that it's rejected a $120/share offer from Amgen (AMGN +0.6%) and that it's seeking buyers after receiving inquiries. There's no shortage of speculation about who could acquire Onyx, with Bayer (BAYZF.PK), Celgene (CELG), Novartis (NVS), Bristol-Myers (BMY), AstraZeneca (AZN), Eli Lilly (LLY), Gilead (GILD) and Pfizer (PFE) all mentioned. However, Forbes' Matthew Herper notes that potential blockbuster blood-cancer drug Kyprolis has only received accelerated FDA approval, which can be revoked. Big Pharma may have wanted to await further trial results later this year amid concerns about Kyprolis' safety.
    | 2 Comments
  • Jun. 27, 2013, 7:45 AM
    Celgene (CELG) has entered into an alliance worth up to €628M, excluding royalties, with Germany's MorphoSys (MPSYF.PK) to develop the latter's MOR202 drug, including for treating the blood cancer multiple myeloma. Celgene will pay €70.8M upfront, €46.2M for new shares in MorphoSys and milestones, while the companies will also share profits. Earlier this month, MorphoSys signed a major licensing deal with GlaxoSmithKline. (PR)
    | Comment!
  • Jun. 20, 2013, 9:18 AM
    Celgene (CELG) announces the presentation of two studies evaluating a Revlimid/ rituximab combo in non-Hodgkins lymphomas. The company's executive vice president for Hematology and Oncology says "The increasing volume of clinical evidence evaluating [these] combinations … provide us powerful insight into the potential of antibody-dependent cellular cytotoxicity in lymphomas." (PR)
    | Comment!
  • Jun. 17, 2013, 11:31 AM
    The European Commission amends the marketing authorization for Celgene's (CELG -0.2%) REVLIMID to include patients with MDS-related transfusion-dependent anemia when other treatments have failed or proven insufficient. The company has pursued clearance for the indication for some 7 years. (previous)
    | Comment!
  • Jun. 16, 2013, 4:24 AM
    Bristol-Myers Squibb's (BMY) and AbbVie's (ABBV) Elotuzumab helped patients with previously-treated multiple myeloma live for a median 33 months without the blood cancer getting worse in a Phase II trial. The drug was given with Celgene's (CELG) Revlimid and the steroid dexamethasone. Elotuzumab is also being tested in two Phase III trials for multiple myeloma. (PR)
    | Comment!
  • Jun. 13, 2013, 7:57 AM
    Celgene's (CELG -0.1%) Apremilast drug significantly improved the signs and symptoms of patients with psoriatic arthritis in the company's "Palace 3" Phase III study. The results come a day after Celgene reported a positive outcome from "Palace I". In total, the company is conducting four Phase III "Palace" trials. (PR)
    | 1 Comment
  • Jun. 12, 2013, 5:17 PM
    Moody's raises Celgene's (CELG) outlook to Positive from Stable citing the "expanding use of Revlimid" (I, II) and "pending approvals of Apremilast in psoriatic arthritis and Abraxane in pancreatic cancer" (I, II) as catalysts for "good growth momentum."
    | Comment!
  • Jun. 12, 2013, 8:11 AM
    Celgene's (CELG +1.6%) board has authorized the repurchase of up to an extra $3B in shares, having exhausted a previous $2.5B buyback program. So far this year, the company has repurchased $1.8B in stock. (See apremilast results) (PR)
    | Comment!
  • Jun. 12, 2013, 8:04 AM
    Celgene (CELG) says 52-week results demonstrate apremilast produces "meaningful improvements" in ACR scores for patients with psoriatic arthritis. The company will present the data at the European Congress of Rheumatology later today. SA contributor Todd Campbell says the drug "offers upside" for CELG shares and notes that "analysts expect apremilast may generate sales of $300-500M/year." Shares +1.5% premarket.
    | Comment!
  • Jun. 11, 2013, 8:40 AM
    Biotech startup Agios Pharmaceuticals has filed to raise $86M in an IPO. The company has raised over a quarter of a billion dollars from VC firms and Celgene (CELG), which has invested $37.5M and made $141.2M in collaboration payments. Celgene has also committed to buying stock in the IPO. Agios has been developing a new approach to treating cancer and metabolic diseases, but has yet to start clinical trials for any of its drug candidates. (S1)
    | 1 Comment
  • Jun. 5, 2013, 3:07 PM
    Celgene (CELG -4.3%) gets FDA approval for its supplemental new drug application for Revlimid to treat mantle cell lymphoma. The drug is already cleared for multiple myeloma, another white blood cell cancer. Analysts estimate the drug could generate around $5.9B in sales in 2016.
    | 3 Comments
  • Jun. 3, 2013, 10:57 AM
    Celgene (CELG -1.5%) trades lower after presentations at ASCO. The company says high-dose chemotherapy and tandem autologous stem cell transplant demonstrated longer median progression-free survival and overall survival than REVLIMID, melphalan, and prednisone. However, a maintenance analysis showed followup treatments with REVLIMID increased progression-free survival and overall survival. (PR)
    | 1 Comment
  • May 31, 2013, 8:16 AM
    The EMA's Committee for Medicinal Products for Human Use (CHMP) gives its blessing to Celgene's (CELG) oral multiple myeloma treatment pomalidomide based on data from a Phase 3 trial. The committee also adopts a positive opinion for Aegerion's (AEGR) HoFH treatment LOJUXTA and says new data does not support the contention that Sanofi's (SNY) Lantus increases the risk of cancer. AEGR + 0.92% premarket.
    | Comment!
  • May 23, 2013, 7:54 AM
    The FDA grants priority review to Celgene's (CELG) NDA for the supplemental use of ABRAXANE alongside gemcitabine for patients with advanced pancreatic cancer. (PR)
    | 1 Comment
  • May 16, 2013, 1:49 PM
    Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%.
    | 1 Comment
Visit Seeking Alpha's
CELG vs. ETF Alternatives
Company Description
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States